SuperworthSilexion Therapeutics SLXN
- Market cap
- $1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −1184.3%
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $535K | $1.3M | $961K+41% | $766K−38% | $3.2M+501% | $871K−31% | $590K−39% | $1M+33% | $2.2M−33% | $3.4M+288% | $1.4M+132% | $2.2M+117% |
| SG&A | $196K | $471K | $289K+128% | $619K+246% | $4.8M+2359% | $1M+119% | $1.1M+267% | $1.3M+105% | $1.1M−76% | $1M+0% | $1.4M+30% | $1.5M+16% |
| −$731K | −$1.7M | −$1.3M+55% | −$1.4M−2% | −$8M+999% | −$1.9M+10% | n/a | −$2.3M+65% | −$3.3M−59% | −$4.4M+132% | n/a | −$3.7M+61% | |
| Pre-tax income | −$803K | −$1.7M | −$1.4M+94% | −$1.5M−20% | −$11.9M+1377% | −$1.7M+4% | −$1.7M+22% | −$2.5M+68% | −$3.3M−73% | −$4.4M+153% | −$2.7M+58% | −$3.6M+42% |
| $6K | $6K | $5K−50% | $2K−80% | $2K−67% | $1K−83% | n/a | $3K+50% | $0 | $0 | n/a | n/a | |
| Net income | −$809K | −$1.7M | −$1.4M+92% | −$1.5M−21% | −$11.9M+1366% | −$1.7M+4% | −$1.7M+22% | −$2.5M+68% | −$3.3M−73% | −$4.4M+153% | −$2.7M+58% | −$3.6M+42% |
| $1053.00 | n/a | $1843.50−56% | $1978.00−78% | $2742.50+160% | n/a | $38.40−98% | $43.19−98% | $28.80−99% | n/a | $8.50−78% | $5.17−88% | |
| 745 | n/a | 745+298% | 744+298% | 4.3K+480% | n/a | 45.2K+5968% | 58K+7687% | 113.3K+2521% | n/a | 323K+615% | 687.4K+1086% |
R&D: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
SG&A: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Operating income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Income tax: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Net income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: Q1 FY23 and Q2 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY23: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Silexion Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SLXNSilexion Therapeutics | $1M | n/m | n/a | n/m | n/m | n/m | |
| CRISCuris | $807.4K | n/m | n/a | 0.2× | −62% | n/m | |
| CLDICalidi Biotherapeutics | $1.6M | n/m | 23.9× | n/m | n/m | n/m | |
| VIVSVivoSim Labs, INC. | $2.2M | n/m | n/a | 19.7× | −21% | n/m | |
| PMCBPharmaCyte Biotech | $3.8M | n/m | n/a | n/a | n/m | n/a | |
| LIMNLiminatus Pharma | $3.9M | n/m | n/a | n/m | n/m | n/m | |
| AIMAIM ImmunoTech | $4.8M | n/m | n/a | 50.1× | −21% | n/m | |
| CELZCreative Medical Technology | $4.9M | n/m | n/a | n/m | −50% | n/m | |
| SNTISenti Biosciences | $5.9M | n/m | n/a | n/m | n/m | n/m | |
| INABIN8BIO | $10.4M | n/m | n/a | n/m | n/m | n/m | |
| INTSIntensity Therapeutics | $10.6M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $4.4M | n/a | 23.9× | 19.7× | −36% | n/a |
More on Silexion Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .